Ken Griffin Atea Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.17 - $4.02 $348,383 - $441,797	-109,900 Reduced 79.12%	29,000 $97,000
Q2 2024 Aug 14, 2024	BUY	$3.31 - $4.04 $21,184 - $25,856	6,400 Added 4.83%	138,900 $459,000
Q1 2024 May 15, 2024	BUY	$3.09 - $4.56 $400,773 - $591,432	129,700 Added 4632.14%	132,500 $535,000
Q4 2023 Feb 14, 2024	SELL	$2.8 - $3.35 $280 - $335	-100 Reduced 3.45%	2,800 $8,000
Q3 2023 Nov 14, 2023	SELL	$3.0 - $3.79 $9,000 - $11,370	-3,000 Reduced 50.85%	2,900 $8,000
Q2 2023 Aug 14, 2023	SELL	$3.21 - $5.06 $17,976 - $28,335	-5,600 Reduced 48.7%	5,900 $22,000
Q1 2023 May 15, 2023	SELL	$3.0 - $4.97 $4,500 - $7,455	-1,500 Reduced 11.54%	11,500 $38,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $56,549 - $80,210	13,000 New	13,000 $62,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $263M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.